Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press120110.17650/1726-9784-2019-19-2-31-38REVIEWSОБЗОРЫ ЛИТЕРАТУРЫPAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART 2. HPV-ASSOCIATED CANCERS IN RUSSIA. PREVENTIVE HPV VACCINESПАПИЛЛОМАВИРУСНЫЙ КАНЦЕРОГЕНЕЗ. ОСНОВНЫЕ ДОСТИЖЕНИЯ И НЕКОТОРЫЕ ПРОБЛЕМЫ ЧАСТЬ 2. ВПЧ-АССОЦИИРОВАННЫЕ ФОРМЫ РАКА В РОССИИ. ПРОФИЛАКТИЧЕСКИЕ ВПЧ-ВАКЦИНЫhttps://orcid.org/0000-0002-6817-2103VolgarevaG. M.ВолгареваГ. М.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Галина Михайловна Волгарева

115478 Москва, Каширское шоссе, 24

galina.volgareva@ronc.ruN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России1806202019231381706202017062020https://bioterapevt.abvpress.ru/jour/article/view/1201

Cervical cancer (CC) incidence rate made up about 5 % in overall women cancer incidence in Russia in 2015. CC morbidity rose by 24.47 % during 2005–2015. Despite the fact that aggregated standardized cancer mortality rates for both men and women during 2005–2015 declined, women CC mortality increased by 8.3 %. CC is the leading cancer mortality cause in women aged 30–39 years. Moreover growth of oral and pharynx cancer incidence rates in both genders as well as penile cancer in men all indicate to an unfavorable trend. The present Review part contains data on HPV-associated cancers in Russia, vertical HPV transition as well as preventive HPV vaccines.

В России в структуре онкологической заболеваемости женщин на долю рака шейки матки (РШМ) в 2015 г. приходилось около 5 %; прирост заболеваемости РШМ за период с 2005 по 2015 г. составил 24,47 %. Несмотря на то что в целом показатели смертности от злокачественных новообразований за 2005–2015 гг. у мужчин и женщин снизились, смертность женщин от РШМ в этот период выросла на 8,3 %. В возрастной группе 30–39 лет смертность от РШМ выходит на 1-е место среди всех причин смерти от злокачественных новообразований. Помимо этого, у лиц обоих полов в период с 2005 по 2015 г. увеличились показатели заболеваемости раком ротовой полости и глотки, а также раком полового члена у мужчин, что выступает, как и в случае с РШМ, проявлением тревожной тенденции. Настоящая часть обзора посвящена формам рака, ассоциированным с вирусами папилломы человека (ВПЧ), в России, вертикальной передаче ВПЧ, а также профилактическим ВПЧ-вакцинам.

carcinogenesispapillomaviruseshuman papillomavirus vaccineканцерогенезвирусы папилломпрофилактические вакцины против вируса папилломы человека1. Волгарева Г.М. Папилломавирусный канцерогенез. Основные достижения и некоторые проблемы. Часть 1. Общие представления о папилломавирусах. Формы рака, ассоциированные с вирусами папилломы человека. Российский биотерапевтический журнал 2020;19(1):6–12. DOI: 10.17650/1726-9784-2019-19-1-6-12. [Volgareva G.M. Papillomaviral carcinogenesis. Major achievements and certain challenges. Part 1. General notions of papillomaviruses. Human papillomaviruses–associated cancers. Rossiyskiy bioterapevticheskiy zhurnal = Russian Jornal of Biotherapy 2020;19(1):6–12. (In Russ.)].Волгарева Г.М. Папилломавирусный канцерогенез. Основные достижения и некоторые проблемы. Часть 1. Общие представления о папилломавирусах. Формы рака, ассоциированные с вирусами папилломы человека. Российский биотерапевтический журнал 2020;19(1):6–12. DOI: 10.17650/1726-9784-2019-19-1-6-12. [Volgareva G.M. Papillomaviral carcinogenesis. Major achievements and certain challenges. Part 1. General notions of papillomaviruses. Human papillomaviruses–associated cancers. Rossiyskiy bioterapevticheskiy zhurnal = Russian Jornal of Biotherapy 2020;19(1):6–12. (In Russ.)].2. Злокачественные новообразования в России в 2015 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017. [Malignant malformations in Russia in 2015 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow, 2017. (In Russ.)].Злокачественные новообразования в России в 2015 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017. [Malignant malformations in Russia in 2015 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow, 2017. (In Russ.)].3. Ульрих Е.А., Урманчеева А.Ф., Гуркин Ю.А. и др. Первичная профилактика рака шейки матки. Эффективность, безопасность, экономическая приемлемость вакцинации. Обзор. Онкогинекология 2018;28(4):61–71. [Ulrikh E.A., Urmancheeva A.F., Gurkin Yu.A. et al. Primary prevention of cervical cancer. Effectiveness, safety, economic feasibility of vaccination. Oncoginekologiya = Gynecologic Oncology 2018;28(4):61–71. (In Russ.)].Ульрих Е.А., Урманчеева А.Ф., Гуркин Ю.А. и др. Первичная профилактика рака шейки матки. Эффективность, безопасность, экономическая приемлемость вакцинации. Обзор. Онкогинекология 2018;28(4):61–71. [Ulrikh E.A., Urmancheeva A.F., Gurkin Yu.A. et al. Primary prevention of cervical cancer. Effectiveness, safety, economic feasibility of vaccination. Oncoginekologiya = Gynecologic Oncology 2018;28(4):61–71. (In Russ.)].4. Samoilova E.V., Shaikhaev G.O., Petrov S.V. et al. HPV infection in cervical-cancer cases in Russia. Int J Cancer 1995;61(3):337–41. DOI: 10.1002/ijc.2910610311.Samoilova E.V., Shaikhaev G.O., Petrov S.V. et al. HPV infection in cervical-cancer cases in Russia. Int J Cancer 1995;61(3):337–41. DOI: 10.1002/ijc.2910610311.5. Волгарева Г.М., Ермилова В.Д. Обнаружение онкогена Е7 вируса папиллом человека 18 типа у больных раком предстательной железы. Российский биотерапевтический журнал 2019;18(1):37–41. DOI: 10.17650/1726-9784-2019-18-1- 37-41. [Volgareva G.M., Ermilova V.D. Detection of human papillomavirus type 18 oncogene E7 in patients with prostate cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2019;18(1):37–41. (In Russ.)].Волгарева Г.М., Ермилова В.Д. Обнаружение онкогена Е7 вируса папиллом человека 18 типа у больных раком предстательной железы. Российский биотерапевтический журнал 2019;18(1):37–41. DOI: 10.17650/1726-9784-2019-18-1- 37-41. [Volgareva G.M., Ermilova V.D. Detection of human papillomavirus type 18 oncogene E7 in patients with prostate cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2019;18(1):37–41. (In Russ.)].6. Golovina D.A., Ermilova V.D., Zavalishina L.E. et al. Loss of cell differentiation in HPV-associated bladder cancer. Bull Exp Biol Med 2016;161(1):96–8. DOI: 10.1007/s10517-016-3354-x.Golovina D.A., Ermilova V.D., Zavalishina L.E. et al. Loss of cell differentiation in HPV-associated bladder cancer. Bull Exp Biol Med 2016;161(1):96–8. DOI: 10.1007/s10517-016-3354-x.7. Smelov V., Eklund C., Bzhalava D. et al. Expressed prostate secretions in the study of human papillomavirus epidemiology in the male. PLoS One 2013;8(6):66630. DOI: 10.1371/journal.pone.0066630.Smelov V., Eklund C., Bzhalava D. et al. Expressed prostate secretions in the study of human papillomavirus epidemiology in the male. PLoS One 2013;8(6):66630. DOI: 10.1371/journal.pone.0066630.8. Заридзе Д.Г., Максимович Д.М. Профилактика злокачественных новообразований. Успехи молекулярной онкологии 2017;4(2):8–25. DOI: 10.17650/2313-805X-2017-4-2-8-25. [Zaridze D.G., Maksimovich D.M. Prevention of malignant malformations. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2017;4(2):8–25. (In Russ.)].Заридзе Д.Г., Максимович Д.М. Профилактика злокачественных новообразований. Успехи молекулярной онкологии 2017;4(2):8–25. DOI: 10.17650/2313-805X-2017-4-2-8-25. [Zaridze D.G., Maksimovich D.M. Prevention of malignant malformations. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2017;4(2):8–25. (In Russ.)].9. Аксель Е.М., Виноградова Н.Н. Статистика злокачественных новообразований женских репродуктивных органов. Онкогинекология 2018;27(3):64–78. [Aksel E.M., Vinogradova N.N. Malignant malformations statistics of female reproductive organs. Oncoginekologiya = Gynecologic Oncology 2018;27(3):64–78. (In Russ.)].Аксель Е.М., Виноградова Н.Н. Статистика злокачественных новообразований женских репродуктивных органов. Онкогинекология 2018;27(3):64–78. [Aksel E.M., Vinogradova N.N. Malignant malformations statistics of female reproductive organs. Oncoginekologiya = Gynecologic Oncology 2018;27(3):64–78. (In Russ.)].10. Rintala M.A., Grénman S.E., Järvenkylä M.E. et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005;41(12): 1728–33. DOI: 10.1086/498114.Rintala M.A., Grénman S.E., Järvenkylä M.E. et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005;41(12): 1728–33. DOI: 10.1086/498114.11. Koskimaa H.M., Waterboer T., Pawlita M. et al. Human papillomavirus genotypes present in the oral mucosa of newborns and their concordance with maternal cervical human papillomavirus genotypes. J Pediatr 2012;160(5):837–43. DOI: 10.1016/j.jpeds.2011.10.027.Koskimaa H.M., Waterboer T., Pawlita M. et al. Human papillomavirus genotypes present in the oral mucosa of newborns and their concordance with maternal cervical human papillomavirus genotypes. J Pediatr 2012;160(5):837–43. DOI: 10.1016/j.jpeds.2011.10.027.12. Merckx M., Liesbeth W.V., Arbyn M. et al. Transmission of carcinogenic human papillomavirus types from mother to child: a meta-analysis of published studies. Eur J Cancer Prev 2013;22(3):277–85. DOI: 10.1097/CEJ.0b013e3283592c46.Merckx M., Liesbeth W.V., Arbyn M. et al. Transmission of carcinogenic human papillomavirus types from mother to child: a meta-analysis of published studies. Eur J Cancer Prev 2013;22(3):277–85. DOI: 10.1097/CEJ.0b013e3283592c46.13. Trottier H., Mayrand M.H., Coutlee F. et al. Human papillomavirus (HPV) perinatal transmission and risk of HPV persistence among children: design, methods and preliminary results of the HERITAGE study. Papillomavirus Res 2016;2:145–52. DOI: 10.1016/j.pvr.2016.07.001.Trottier H., Mayrand M.H., Coutlee F. et al. Human papillomavirus (HPV) perinatal transmission and risk of HPV persistence among children: design, methods and preliminary results of the HERITAGE study. Papillomavirus Res 2016;2:145–52. DOI: 10.1016/j.pvr.2016.07.001.14. Sarkola M.E., Grenman S.E., Rintala M.A. et al. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand 2008;87(11):1181–8. DOI: 10.1080/00016340802468308.Sarkola M.E., Grenman S.E., Rintala M.A. et al. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand 2008;87(11):1181–8. DOI: 10.1080/00016340802468308.15. Tuominen H., Rautava S., Collado M.C. et al. HPV infection and bacterial microbiota in breast milk and infant oral mucosa. PLoS One 2018;13(11):0207016. DOI: 10.1371/journal.pone.0207016.Tuominen H., Rautava S., Collado M.C. et al. HPV infection and bacterial microbiota in breast milk and infant oral mucosa. PLoS One 2018;13(11):0207016. DOI: 10.1371/journal.pone.0207016.16. Koskimaa H.M., Paaso A., Welters M.J.P. et al. The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization. Eur J Clin Microbiol Infect Dis 2017;36(8):1491–503. DOI: 10.1007/s10096-017-2958-z.Koskimaa H.M., Paaso A., Welters M.J.P. et al. The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization. Eur J Clin Microbiol Infect Dis 2017;36(8):1491–503. DOI: 10.1007/s10096-017-2958-z.17. Tuominen H., Rautava S., Syrjanen S. et al. HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa. Sci Rep 2018;8(1):9787. DOI: 10.1038/s41598-018-27980-3.Tuominen H., Rautava S., Syrjanen S. et al. HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa. Sci Rep 2018;8(1):9787. DOI: 10.1038/s41598-018-27980-3.18. Lee B., Lee S.W., Kim D.I., Kim J.H. HPV prevalence in the foreskins of asymptomatic healthy infants and children: Systematic review and meta-analysis. Sci Rep 2017;7(1):7050. DOI: 10.1038/s41598-017-07506-z.Lee B., Lee S.W., Kim D.I., Kim J.H. HPV prevalence in the foreskins of asymptomatic healthy infants and children: Systematic review and meta-analysis. Sci Rep 2017;7(1):7050. DOI: 10.1038/s41598-017-07506-z.19. Wilson R., Laimins L.A. Differentiation of HPV-containing cells using organotypic “raft” culture or methylcellulose. Methods Mol Med 2005;119:157–69. DOI: 10.1385/1-59259-982-6:157.Wilson R., Laimins L.A. Differentiation of HPV-containing cells using organotypic “raft” culture or methylcellulose. Methods Mol Med 2005;119:157–69. DOI: 10.1385/1-59259-982-6:157.20. Regan J.L., Laimins L.A. Viral transformation of epithelial cells. Methods Mol Biol 2013;945:449–65. DOI: 10.1007/978-1-62703-125-7_26.Regan J.L., Laimins L.A. Viral transformation of epithelial cells. Methods Mol Biol 2013;945:449–65. DOI: 10.1007/978-1-62703-125-7_26.21. Dadar M., Chakraborty S., Dhama K. et al. Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus. Front Immunol 2018;2478(9):32. DOI: 10.3389/fimmu.2018.02478.Dadar M., Chakraborty S., Dhama K. et al. Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus. Front Immunol 2018;2478(9):32. DOI: 10.3389/fimmu.2018.02478.22. IARC Monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. 100 Part B: Biological agents. Lyon, 2011.IARC Monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. 100 Part B: Biological agents. Lyon, 2011.23. Dillner J., Arbyn M., Unger E., Dillner L. Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2011;163(1):17–25. DOI: 10.1111/j.1365-2249.2010.04268.xDillner J., Arbyn M., Unger E., Dillner L. Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2011;163(1):17–25. DOI: 10.1111/j.1365-2249.2010.04268.x24. Pagliusi S.R., Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23(5):569–78. DOI: 10.1016/j.vaccine.2004.07.046.Pagliusi S.R., Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23(5):569–78. DOI: 10.1016/j.vaccine.2004.07.046.25. Lowy D.R., Frazer I.H. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003;(31):111–6. DOI: 10.1093/oxfordjournals.jncimonographs.a003472.Lowy D.R., Frazer I.H. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003;(31):111–6. DOI: 10.1093/oxfordjournals.jncimonographs.a003472.26. Joura E.A., Giuliano A.R., Iversen O.E. et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372(8):711–23. DOI: 10.1056/NEJMoa1405044.Joura E.A., Giuliano A.R., Iversen O.E. et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372(8):711–23. DOI: 10.1056/NEJMoa1405044.27. Garland S.M., Pitisuttithum P., Ngan H.Y.S. et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Inf Dis 2018;218(1):95–108. DOI: 10.1093/infdis/jiy133.Garland S.M., Pitisuttithum P., Ngan H.Y.S. et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Inf Dis 2018;218(1):95–108. DOI: 10.1093/infdis/jiy133.28. Human papillomavirus vaccines: WHO position paper, may 2017. WHO, weekly epidemiological record 2017;92(19):241–68.Human papillomavirus vaccines: WHO position paper, may 2017. WHO, weekly epidemiological record 2017;92(19):241–68.29. Daley E.M., Vamos C.A., Thompson E.L. et al. The feminization of HPV: how science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Res 2017;3:142–48. DOI: 10.1016/j.pvr.2017.04.004.Daley E.M., Vamos C.A., Thompson E.L. et al. The feminization of HPV: how science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Res 2017;3:142–48. DOI: 10.1016/j.pvr.2017.04.004.30. Волгарева Г.М. Естественная циркуляция вирусов папилломы человека у мужчин: что о ней известно? Российский биотерапевтический журнал 2018;17(1):28–33. DOI: 1017650/1726-9784-2018-17-1-28-33. [Volgareva G.M. Natural history of papillomaviruses in men – what is known? Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2018;17(1):28–33. (In Russ.)].Волгарева Г.М. Естественная циркуляция вирусов папилломы человека у мужчин: что о ней известно? Российский биотерапевтический журнал 2018;17(1):28–33. DOI: 1017650/1726-9784-2018-17-1-28-33. [Volgareva G.M. Natural history of papillomaviruses in men – what is known? Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2018;17(1):28–33. (In Russ.)].31. Zur Hausen H. Papillomaviruses – to vaccination and beyond. Biochemistry (Moscow) 2008;73(5):498–503. DOI: 10.1134/S0006297908050027.Zur Hausen H. Papillomaviruses – to vaccination and beyond. Biochemistry (Moscow) 2008;73(5):498–503. DOI: 10.1134/S0006297908050027.32. Zur Hausen H., Mammas I.N., Spandidos D.A. HPV vaccination in boys: determining the clinical relevance of this strategy. Exp Ther Med 2017;14(4):3327–8. DOI: 10.3892/etm.2017.5005.Zur Hausen H., Mammas I.N., Spandidos D.A. HPV vaccination in boys: determining the clinical relevance of this strategy. Exp Ther Med 2017;14(4):3327–8. DOI: 10.3892/etm.2017.5005.33. Giuliano A.R., Palefsky J.M., Goldstone S. et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364(5):401–11. DOI: 10.1056/NEJMoa0909537.Giuliano A.R., Palefsky J.M., Goldstone S. et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364(5):401–11. DOI: 10.1056/NEJMoa0909537.34. Pinto L.A., Kemp T.J., Torres B.N. et al. Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine Trial. J Infect Dis 2016;214(8):1276–83. DOI: 10.1093/infdis/jiw359.Pinto L.A., Kemp T.J., Torres B.N. et al. Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine Trial. J Infect Dis 2016;214(8):1276–83. DOI: 10.1093/infdis/jiw359.35. WHO position paper on vaccines against human papillomavirus(HPV). Summary of key points. WHO, Geneva, 2017.WHO position paper on vaccines against human papillomavirus(HPV). Summary of key points. WHO, Geneva, 2017.36. Drolet M., Benard E., Boily M.C. et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;5(5):565–80. DOI: 10.1016/S1473-3099(14)71073-4.Drolet M., Benard E., Boily M.C. et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;5(5):565–80. DOI: 10.1016/S1473-3099(14)71073-4.37. Couto E., Saeterdal I., Juvet L.K., Klemp M. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 2014; 14:867. DOI: 10.1186/1471-2458-14-867.Couto E., Saeterdal I., Juvet L.K., Klemp M. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 2014; 14:867. DOI: 10.1186/1471-2458-14-867.38. Goggin P., Sauvageau C., Gilca V. et al. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada. Hum Vaccin Immunother 2018;14(1):118–23. DOI: 10.1080/21645515.2017.1385688.Goggin P., Sauvageau C., Gilca V. et al. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada. Hum Vaccin Immunother 2018;14(1):118–23. DOI: 10.1080/21645515.2017.1385688.39. Looker K.J., Rönn M.M., Brock P.M. et al. Evidence of synergistic relationships between HIV and human papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Society 2018; 21(6):25110. DOI: 10.1002/jia2.25110.Looker K.J., Rönn M.M., Brock P.M. et al. Evidence of synergistic relationships between HIV and human papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Society 2018; 21(6):25110. DOI: 10.1002/jia2.25110.